NEXTBIOMEDICAL Receives FDA Breakthrough Device Designation for Nexsphere-F™ Resorbable Microsphere

NEXTBIOMEDICAL has announced that its innovative product, Nexsphere-F™, has received Breakthrough Device Designation from the United States Food and Drug Administration (FDA). Nexsphere-F™ is a resorbable microsphere designed for musculoskeletal pain embolisation.

The Breakthrough Device Designation is granted to medical devices that offer significant improvements over existing treatments and address urgent clinical needs. 

This recognition allows for close collaboration with the FDA, priority review, and an expedited regulatory process. It also provides greater flexibility in clinical trial design, which can help accelerate the product's entry into the market.

Nexsphere-F™ is intended for the treatment of knee osteoarthritis (OA) pain in patients who have not responded adequately to conservative non-pharmacological therapy or pain relief medications. 

The device works by temporarily blocking blood flow in the genicular arteries using advanced resorbable microsphere technology. 

These microspheres dissolve within two to six hours, leading to the destruction of pain-inducing nerve cells and providing rapid pain relief.

Having already secured FDA approval for its Investigational Device Exemption (IDE), Nexsphere-F™ is set to undergo a pivotal clinical trial in leading university hospitals across the United States. The trial will include approximately 120 patients. 

This recognition by the FDA is expected to facilitate the regulatory approval process and enhance collaboration with global medical device companies. 

NEXTBIOMEDICAL aims to leverage this breakthrough designation to expand its market presence and establish a strong position in the medical device industry, both in the United States and internationally.